louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06989021: Forward Head Posture and Hand Function in Dentists
Official title: CORRELATION BETWEEN HAND, PINCH GRIP STRENGTH, WRIST JOINT POSITION SENSE AND FORWARD HEAD POSTURE AMONG DENTISTS
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Forward Head Posture
Keywords: Craniovertebral Angle Hand Function Posture Assessment Wrist Proprioception
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-05-25
Enrollment: 82
Sex: ALL
Minimum age (years): 23
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and female dentists aged 23-30 years, including residents, interns, and senior dental students, with forward head posture (craniovertebral angle \< 50°), recruited from the Faculty of Dentistry at Kafr El-Sheikh University. Participants must have a BMI between 18.5 and 29.9 kg/m² and no history of neurological or orthopedic disorders affecting the upper limb or cervical spine.

Brief summary: This observational study investigates the correlation between forward head posture and hand grip strength, pinch grip strength, and wrist joint position sense among dentists aged 23-30 years. The aim is to understand the impact of poor head posture on upper limb function in dental professionals.

Detailed description: The study evaluates the relationship between craniovertebral angle and upper limb strength and proprioception using hand dynamometers, pinch gauges, and goniometers. Forward head posture is assessed photometrically. A total of 82 participants will be recruited, all dentists, aged 23-30 years, with FHP confirmed by CVA \<50°. Hand grip, pinch grip (tip, palmar, lateral), and wrist joint position sense (flexion/extension) will be assessed in the dominant hand only.

Eligibility criteria: Inclusion Criteria:

* Male and female dentists

Aged 23-30

BMI 18.5-29.9 kg/m²

Dominant hand used for testing

Forward head posture (CVA \< 50°)

Exclusion Criteria:

* History of cervical trauma or surgery

Cervical radiculopathy or disc herniation

Upper limb neurological or orthopedic disorders

Dizziness, blurred vision, or neck/shoulder pain

Primary outcomes:
measure: Hand Grip Strength
timeFrame: Single assessment at baseline
Secondary outcomes:
measure: Pinch Grip Strength
timeFrame: Single assessment at baseline
measure: Wrist Joint Position Sense
timeFrame: Single assessment at baseline
Other outcomes:
Locations:
Study officials:
affiliation: Cairo University
name: Hadeer Essam Mohamed, Bachelor's Degree
role: PRINCIPAL_INVESTIGATOR
affiliation: Cairo University
name: ENAS FAWZY YOUSSEF, PT, PhD
role: STUDY_CHAIR
References:
citation: Celik HI, Unver B, Akbas E, Erdem EU. Head posture mediates the association of cognition with hand grip and pinch strength in older adults: an examination using structural equation modeling. BMC Musculoskelet Disord. 2023 Apr 25;24(1):324. doi: 10.1186/s12891-023-06436-4.
Clinical trial NCT00461721: Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis
Official title: Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis Due to Grass Pollen During Immunotherapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Allergy
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2007-04-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: x

Brief summary: To find a test to elaborate a parameter for specific immunotherapy in allergic patients


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 65
* Signed informed consent
* SIT 2000/2001
* 10 patients with SIT with a good result- 10 patients with bad results

Exclusion criteria:

* Pregnancy and breastfeeding

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Department of Dermatology
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT06844864: Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Official title: Identification of Adaptive and Trained Immune Mechanisms Driving Tissue Fibrosis in IgG4-Related Disease
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: IgG4 Related Disease
Keywords: Trained immunity
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2025-02-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with IgG4-related disease and healthy controls

Brief summary: Enquire involvement of trained immunity in the pathogenesis of IgG4RD

Detailed description: Enquire involvement of trained immunity in the pathogenesis of IgG4RD using primary macrophages and co-cultures with patient derived fibroblasts. The investigators will first assess whether macrophages from patients are trained compared to macrophages of healthy controls and then challenge them with IgG from IgG4RD patients to evaluate the functional effects on cultivated fibroblasts.

Eligibility criteria: Inclusion Criteria:

Patients:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent
* Active IgG4-RD based on the IgG4-related disease activity index
* Fulfillment of the 2019 ACR/EULAR Classification Criteria for IgG4RD

Healthy Controls:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent

Exclusion Criteria:

Patients and healthy controls:

* Subjects \< 18 years of age
* Pregnant women
* Comorbidities (other ongoing active autoimmune diseases, ongoing cancer, ongoing infections)
* Ongoing immunosuppressive therapy

Primary outcomes:
measure: Concentration of collagen Ia in the supernant of macrophage/fibroblast co-cultures
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Ospedale San Raffaele
state: MI
Study officials:
References:
Clinical trial NCT04655664: The Use of the 25 (OH) D Saliva Test as a Substitute for the 25 (OH) D Serum Test in Healthy People
Official title: The Use of the 25 (OH) D Saliva Test as a Substitute for the 25 (OH) D Serum Test in Healthy People
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nutritional Deficiency
Keywords: vitamin D
cross-sectional
non-invasive
correlation
deficiency
insufficiency
Lead sponsor: Universitas Sumatera Utara
Sponsor class: OTHER
First posted: 2020-12-07
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Routine examination of vitamin D levels is carried out by checking serum 25 (OH)D levels, which indicate circulating vitamin D levels. While serum 1.25 (OH) D levels are less frequently utilized, they represent the active form of vitamin D and could be a substitute for checking vitamin D levels. This study aims to find the correlation between vitamin D levels, namely 25 (OH) D and 1.25 (OH) D saliva, which correlate with serum 25 (OH) D and 1.25 (OH) D levels in the examination of salivary vitamin D, and which could be a substitute for checking serum vitamin D levels.

Detailed description: Routine examination of vitamin D levels is carried out by checking serum 25 (OH)D levels, which indicate circulating vitamin D levels. While serum 1.25 (OH) D levels are less frequently utilized, they represent the active form of vitamin D and could be a substitute for checking vitamin D levels.This study aims to find the correlation between vitamin D levels, namely 25 (OH) D and 1.25 (OH) D saliva, which correlate with serum 25 (OH) D and 1.25 (OH) D levels in the examination of salivary vitamin D, and which could be a substitute for checking serum vitamin D levels.This study is a cross-sectional study involving healthy men and women, aged 20-50 years, from Lima Puluh Village, Batubara District, North Sumatra Province, Indonesia. The parameters studied were 25 (OH) D and 1.25 (OH) D levels of saliva and serum.

Eligibility criteria: Inclusion Criteria:

* men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders.

Exclusion Criteria:

* subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.

Primary outcomes:
measure: Salivary 25 (OH) D
timeFrame: up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Medan
country: Indonesia
facility: Faculty of Medicine Universitas Sumatera Utara
state: North Sumatra
Study officials:
References:
Clinical trial NCT01028664: Use of an Ocular Telemetry Sensor in Diamox Treated Patients
Official title: Detection of IOP Fluctuation With SENSIMED Triggerfish in Patients With Glaucoma or Ocular Hypertension Treated With Diamox
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Ocular Hypertension
Keywords: Glaucoma and ocular hypertension patients
Lead sponsor: Sensimed AG
Sponsor class: INDUSTRY
Collaborators: name: Clinique de Montchoisi, Lausanne, Switzerland
First posted: 2009-12-09
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: A soft contact lens integrating a Sensor is placed on subjects with high intraocular pressure (IOP) after administration of an IOP-lowering drug to investigate the device's capacity to detect the induced IOP reduction.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of glaucoma or ocular hypertension
* IOP of ≥ 15 mmHg.
* Patients of either gender.
* Older than 18 years.
* Patients who accept signing an informed consent approved by the Ethics Committee.

Exclusion Criteria:

* Patients not able to understand the nature of the research
* Patients under tutorship
* Corneal abnormalities in both eyes
* Subjects with contraindications for wearing contact lenses
* History of ocular surgery within the last 3 months
* Known hypersensitivity to Diamox® or to any of its excipients
* Pregnancy and lactation
* Simultaneous participation in other clinical research
* Patients with evidence of ocular infection or inflammation
* History of renal or hepatic impairment, hypokalemia and hyponatremia

Primary outcomes:
measure: Detection of IOP reduction 2 hours after Diamox administration
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Clinique de Montchoisi, Centre du Glaucome
Study officials:
References:
Clinical trial NCT03317964: Genetic Basis of Pacing-induced Cardiomyopathy
Official title: Genetic Basis of Pacing-Induced Cardiomyopathy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pacemaker, Artificial
Cardiomyopathies
Lead sponsor: The Guthrie Clinic
Sponsor class: OTHER
First posted: 2017-10-23
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen at Robert Packer Hospital, Sayre, PA

Brief summary: The purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.

Detailed description: DNA will be extracted from the saliva to test for changes in genes related to cardiomyopathy.

Eligibility criteria: Inclusion Criteria:

* Patients who have been assessed for cardiomyopathy

Exclusion Criteria:

* Patients who do not have adequate follow up care to determine if they do or do not have cardiomyopathy

Primary outcomes:
measure: Number of participants with genotype frequency
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sayre
country: United States
facility: Robert Packer Hospital
state: Pennsylvania
Study officials:
affiliation: The Guthrie Clinic
name: Pramod Deshmukh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06740864: 40 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations
Official title: Induction and Stabilization of Gamma Oscillations With 40 Hz Transcranial Alternating Current Stimulation in Healthy Elderly
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Cognitive Decline
Lead sponsor: The National Brain Mapping Laboratory (NBML)
Sponsor class: OTHER
Collaborators: name: Technical University of Dortmund
name: Leibniz Research Centre for Working Environment and Human Factors
name: Institute for Research in Fundamental Sciences (IPM)
First posted: 2024-12-18
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study aims to compare the efficacy of different 40 Hz tACS protocols in entraining gamma oscillations, which are linked to various cognitive functions and play a significant role in cognitive impairments like Alzheimer's disease. Specifically, it examines the effects of 40 Hz tACS applied to frontal brain regions versus fronto-temporal regions on gamma oscillations and working memory in healthy elderly individuals.


Eligibility criteria: Inclusion Criteria:

* healthy elderly between 50-80 years of age
* normal or corrected to normal eye vision
* right-handed
* non-smokers
* at least 70 % accuracy in working memory training task

Exclusion Criteria:

* history of neurological or psychiatric disorders including seizures or epilepsy,
* Taking CNS, blood pressure and other medications
* having metal implants in the head and neck
* significant cognitive decline meassured by The Montreal Cognitive Assessment (MoCA)

Primary outcomes:
measure: Working Memory behavioral performance
timeFrame: During procedure (20 minutes)
measure: electroencephalogram (EEG) oscillatory power
timeFrame: up to 2 hours after the intervention
measure: electroencephalogram (EEG) functional connectivity
timeFrame: up to 2 hours after the intervention
Secondary outcomes:
measure: electroencephalogram (EEG) oscillatory power
timeFrame: up to 2 hours after the intervention
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Institute for Research in Fundamental Sciences
Study officials:
References:
Clinical trial NCT00780364: Sour Taste and Cold Temperature in Dysphagia
Official title: Sour Taste and Cold Temperature Effects on Pharyngeal Transit Time After Ischemic Stroke:Anatomic and Functional Bases.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Stroke
Keywords: stroke; sour taste; cold temperature; pharyngeal swallowing
Lead sponsor: UPECLIN HC FM Botucatu Unesp
Sponsor class: OTHER
First posted: 2008-10-27
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients in hospital

Brief summary: The objective is to establish the effect of sour taste and cold temperature on the pharyngeal swallowing transit time after ischemic hemisphere stroke.

Detailed description: Over the past decade there were many studies over normal and pathological swallowing that discuss the influence of taste and temperature. Nevertheless there were many questions on the issue that remains to be solved, including the hemispheric lateralization of lesions dysphagic patients remains also to be fully understood.Swallowing disorder is defined as oropharyngeal dysphagia in presence of alterations in any phase of the complex swallowing dynamics. It could be congenital or acquired, affecting nutritional aspects, hydration, lung function and the individual's social integration \[1\]. Stroke, has a high incidence among neurological diseases, and cause disturbs on swallowing dynamics presenting signs of dysphagia in at least 50% of cases.A study that analyzed swallowing dynamics by videofluoroscopy in individuals with history of one or more stroke episodes with oropharyngeal dysphagia shows shorter pharyngeal and oropharyngeal transit times with cold stimulus than without them. Other study of heterogeneous neurological diseases such as cerebral palsy, brain trauma, stroke, and Alzheimer's disease, concluded that sour taste improved swallowing, minimizing laryngotracheal penetration and aspiration in individuals with neurological damaged. Chen et al. in an analysis of 42 healthy individuals with several taste bolus found that awareness and arousal could also influence the swallowing function.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of stroke

Exclusion Criteria:

* instability clinic

Primary outcomes:
measure: Sour Taste and Cold Temperature in Dysphagia
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Botucatu
country: Brazil
facility: Sao Paulo State University
state: Sao Paulo
Study officials:
affiliation: São Paulo State University
name: Paula C Cola, master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06738264: Cardiovascular Risk Factors in Rheumatoid Arthritis Patients ( Comparison Between Seronegative and Seropositive Cases )
Official title: Cardiovascular Risk Factors in Rheumatoid Arthritis Patients ( Comparison Between Seronegative and Seropositive Cases )
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Rheumatoid Arthritis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-12-17
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: rheumatology outpatient clinic

Brief summary: The goal of this observational study is to learn about the long-term effects rheumatoid arthritis (RA) on cardiovascular system. The main question it aims to answer is:

Does seropositive raise risk of cardiovascular diseases more than seronegative RA ?

Detailed description: We will investigate cardiovascular risk factors in patients with seronegative and seropositive rheumatoid arthritis.

Complete clinical examination including blood pressure (BP; using an automatic BP monitor) and heart rate (in beats per minute (bpm) either from an automatic BP monitor or a 12 lead ECG) will be measured according to the standard hospital procedures.

Routine Laboratory investigations, including complete blood count (CBC), Blood parameters, including autoantibodies and lipid profile will be determined), liver and kidney function tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and lipid profile panel will be recorded.

The disease activity score-28 (DAS-28) and health assessment questionnaire (HAQ) will be assessed.

Framingham risk score will be calculated. Carotid doppler will be done . Current medications use including synthetic disease-modifying anti-rheumatic drugs (DMARDs), in addition to steroids, will be recorded.

Rheumatoid Factor and Anticitrullinated proteins antibodies presence will be determined.

Cardiovascular risk factors, including inflammation, hypertension, smoking, obesity, and dyslipidemia will be observed and a higher risk of Cardiovascular Diseases events (including myocardial infarction, stroke, and heart failure).

Eligibility criteria: Inclusion Criteria:

* Adult patients ≥ 18 years.
* Both sexes.
* All patients with RA confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology EULAR classification criteria
* RA diagnosed for at least six months to ensure chronicity.

Exclusion Criteria:

* Diagnosis of other significant autoimmune diseases (e.g., lupus, scleroderma).
* Use of medications known to significantly affect cardiovascular outcomes (e.g., certain anticoagulants or anti-inflammatory agents) that are not part of standard RA treatment.

Primary outcomes:
measure: carotid artery wall thickness
timeFrame: one week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02697864: A Study Comparing Amounts of Tafamidis In The Blood Without Food
Official title: A Phase 1, Open-Label, Three Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf-06291826 (Tafamidis) Free Acid Tablet Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2016-03-03
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: 3 different formulations and doses of tafamidis will be compared. Subjects will be fasted for each test and every subject will test all 3 different formulations. After swallowing tafamidis, tafamidis blood concentrations will be measured periodically for 6 days. After 14 days, subjects will take a different formulation of tafamidis and tafamidis blood concentrations will be measured periodically for 6 days. After another 14 days, the last formulation will be tested in the same way.


Eligibility criteria: Inclusion Criteria:

* Healthy males or females of non-child bearing potential.
* Body Mass Index (BMI) of 17.5 to 30.5 and total body weight more than 50 kg (110 lbs).

Exclusion Criteria:

* Blood pressure at screening visit of greater than 140 mm Hg (systolic) or 90 mg Hg (diastolic).
* Use of prescription or nonprescription drugs supplements within 7 days prior to 7 days of the study.
* Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception.

Primary outcomes:
measure: Area under the concentration-time Curve (AUC)
timeFrame: 120 hours
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 120 hours
Secondary outcomes:
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
timeFrame: 120 hours
measure: Mean residence time (MRT)
timeFrame: 120 hours
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 120 hours
measure: Plasma Decay Half-Life (t1/2)
timeFrame: 120 hours
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Pfizer Clinical Research Unit
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: